108
Views
0
CrossRef citations to date
0
Altmetric
News & views

Are antibodies against PCSK9 the statins of the 21st century?

&
Pages 141-144 | Published online: 18 Jan 2017

References

  • Koren MJ, Giugliano RP, Raal FJ et al.; OSLER Investigators. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 29(2), 234–243 (2013).
  • Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354(12), 1264–1272 (2006).
  • Desai NR, Giugliano RP, Zhou J et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of NCEP-ATP III LDL-C goals among high risk patients: an analysis from the LAPLACE-TIMI 57 trial. J. Am. Coll. Cardiol. 63(5), 430–433 (2013). • First large study with evolocumab.
  • Abifadel M, Varret M, Rabes JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34(2), 154–156 (2003). •• First large epidemiological study to highlight the importance of PCSK9.
  • Koren MJ, Scott R, Kim JB et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, Phase 2 study. Lancet 380(9858), 1995–2006 (2012).
  • Sullivan D, Olsson AG, Scott R et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308(23), 2497–2506 (2012). • First study with evolocumab monotherapy for statin-intolerant patients.
  • Raal F, Scott R, Somaratne R et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126(20), 2408–2417 (2012).
  • Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J. Lipid Res. 53(12), 2515–2524 (2012). •• The review that elucidated the role of PCSK9.
  • Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem. Biophys. Res. Commun. 375(1), 69–73 (2008).
  • Graham MJ, Lemonidis KM, Whipple CP et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48(4), 763–767 (2007).
  • Lindholm MW, Elmén J, Fisker N et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol. Ther. 20(2), 376–381 (2012).
  • Mikhailidis DP, Athyros VG. Year in review 2013: dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat. Rev. Cardiol. 11(2), 72–74 (2013).
  • Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). http://clinicaltrials.gov/ct2/show/NCT01764633?term=FOURIER&rank=1
  • US FDA. How Drugs are Developed and Approved. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/default.htm
  • Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/ AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. doi.org/10.1016/j.jacc.2013.11.002 (2013) (Epub ahead of print). •• The recent american college of cardiology (ACC)/ american heart association (AHA) lipid guidelines.
  • Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Hypolipidaemic drug treatment: yesterday is not gone yet, today is challenging and tomorrow is coming soon, let us combine them all. Curr. Pharm. Des. (2014) (In press).
  • Navarese EP, Buffon A, Andreotti F et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am. J. Cardiol. 111(8), 1123–1130 (2013). •• The meta-analysis that linked statins with new-onset diabetes.
  • Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 131(11), 1427–1434 (2013).
  • Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann. Pharmacother. 46(4), 549–557 (2012).
  • Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr. Pharm. Des. 15(5), 479–489 (2009).
  • Athyros VG, Mikhailidis DP, Papageorgiou AA et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J. Clin. Pathol. 57(7), 728–734 (2004).
  • Athyros VG, Elisaf M, Papageorgiou AA et al. GREACE Study Collaborative Group: effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am. J. Kidney Dis. 43(4), 589–599 (2004).
  • Athyros VG, Tziomalos K, Gossios TD et al. GREACE Study Collaborative Group: safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet 376, 1916–1922 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.